SCHEMBL25202606

SCHEMBL25202606

COC(=O)c1sc(Br)cc1S(=O)(=O)Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.38
KMT2A Q03164 3/20 0.38
TSHR P16473 2/20 0.38
HSD17B10 Q99714 1/20 0.38
GSK3B P49841 1/20 0.38
LMNA P02545 7/20 0.37
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 5/20 0.37
PKM P14618 2/20 0.37
PPARG P37231 2/20 0.36
NCOA1 Q15788 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
NCOA3 Q9Y6Q9 2/20 0.36
NCOA2 Q15596 1/20 0.36
RAB9A P51151 2/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPC1 O15118 1/20 0.35
CASP3 P42574 1/20 0.35
SENP8 Q96LD8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25202684 0.85 VCAM1 (0.39) MAPTKMT2ATSHRHSD17B10GSK3B
SCHEMBL25201620 0.84 CA2 (0.45) MAPTKMT2ATSHRHSD17B10GSK3B
SCHEMBL3019240 0.83 KDM4E (0.46) MAPTKMT2ATSHRHSD17B10LMNA
SCHEMBL3016567 0.82 MAPT (0.40) MAPTKMT2ATSHRHSD17B10LMNA
SCHEMBL8779802 0.81 KDM4E (0.40) MAPTKMT2ATSHRHSD17B10LMNA
SCHEMBL319034 0.79 GSK3B (0.53) MAPTKMT2ATSHRHSD17B10GSK3B
SCHEMBL11014523 0.77 MAPT (0.43) MAPTKDM4EPKMNPSR1NPC1
SCHEMBL26962809 0.76 MAPT (0.42) MAPTKMT2ATSHRHSD17B10GSK3B
SCHEMBL4360547 0.75 MAPT (0.58) MAPTKMT2AHSD17B10LMNAALDH1A1
SCHEMBL2730725 0.74 MAPT (0.44) MAPTKMT2ATSHRHSD17B10GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. 2025-05-08 US disclosed
EP-4433059-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF Erasca, Inc. (US) 2024-09-25 EP disclosed
WO-2023215494-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-11-09 WO disclosed
WO-2023087027-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ULK1, ULK2, ULK3 MAPT 710/4885KMT2A 2646/4885TSHR 3373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.